Alzheimer’s disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI
Neil Graham(Imperial College London), David Sharp(Albert Einstein College of Medicine), Arturo Chieregato, Guido Bertolini(Mario Negri Institute for Pharmacological Research), Vincent Dunet(University Hospital of Lausanne), Ashvini Keshavan(University College London), Jonathan M. Schott(UK Dementia Research Institute), Elena Garbero(Mario Negri Institute for Pharmacological Research), Karl Zimmerman(Imperial College London), Sandra Magnoni(University of Cambridge), Enrico Fainardi(Vita-Salute San Raffaele University), Adriano Bernini(Centre Hospitalier Universitaire Vaudois), Amanda Heslegrave(UK Dementia Research Institute), Giovanni Nattino(Ohio Department of Health), Henrik Zetterberg(University of Wisconsin–Madison), Mauro Oddo(IMT School for Advanced Studies Lucca), Federico Moro(Mario Negri Institute for Pharmacological Research), Primož Gradišek(Ljubljana University Medical Centre), Camelia Baciu(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Samia Abed‐Maillard
Cited by 8
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
Brain age predicts mortality
|Molecular Psychiatry|2017|881
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
|The Lancet Neurology|2017|630